# Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)

> **NCT06766825** · PHASE2 · RECRUITING · sponsor: **Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia** · enrollment: 90 (estimated)

## Conditions studied

- Post COVID-19 Condition
- Long COVID Syndrome
- Persistent COVID-19
- Persistent COVID Condition
- Long COVID

## Interventions

- **DRUG:** Plitidepsin 1.5 mg/day
- **DRUG:** Placebo
- **DRUG:** Placebo and Plitidepsin 1.5mg/day

## Key facts

- **NCT ID:** NCT06766825
- **Lead sponsor:** Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-07
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-09-01
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-04-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06766825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06766825, "Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06766825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*